A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by Oslo University Hospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Ullevaal University Hospital
Collaborator:
Mundipharma AB
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01109511
First received: April 15, 2010
Last updated: July 20, 2011
Last verified: April 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Objectives:
Primary objective:
- To demonstrate that the treatment with OXN PR tablets up to 72 hrs after surgery is superior to the treatment with OxyPR with regards to constipation in subjects with postoperative pain after laparoscopic hysterectomy based on interviews 24h, 72 h and 1 week postoperatively.
The secondary objectives:
- Analgesic effect (including registration during the first 24 hrs)
- To asses the frequency of pain rescue mediation use (in the double-blind phase, 0-72 hrs)
- Frequency of nausea and vomiting
- Frequency of other adverse events
- Appetite
- Mobilization
The exploratory objectives:
- Overall patient satisfaction at 24, 72 hrs and 1 week
| Condition | Intervention | Phase |
|---|---|---|
|
Postoperative Pain Opioid Induced Constipation |
Drug: naloxone Drug: oxycodone |
Phase 4 |
| Study Type: | Interventional |
Resource links provided by NLM:
Further study details as provided by Oslo University Hospital:
Primary Outcome Measures:
- Constipation in subjects with postoperative pain
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | July 2011 |
| Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: oxycodone+naloxone | Drug: naloxone Drug: oxycodone |
|
Active Comparator: Control
Oxycodone alone without naloxone
|
Drug: oxycodone |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Female |
Criteria
Inclusion Criteria:
- Females 18 -70 years
- Elective, non-malignant laparoscopic gynecological surgery in general anesthesia : hysterectomy/ myomectomy, ASA 1, 2 and 3
- Subjects willing and able to participate the study and have provided informed consent form -
Exclusion Criteria:
- Previous recent or regular opioid use (WHO step I pain treatment allowed)
- Any situation where opioids are contraindicated.
- Any history of moderate to severe hepatic impairment.
- Any history of severe respiratory depression with hypoxia and/or hypercapnia
- Any history of severe chronic obstructive pulmonary disease, cor pulmonal, acute severe bronchial asthma
- Subjects with evidence of non-opioid induced paralytic ileus
- Subjects with evidence of severely impaired pulmonary function, myxoedema, hypothyroidism
- Subjects with evidence of Addison's disease (adrenal cortical insufficiency), toxic psychosis,cholelithiasis, prostate hypertrophy, alcoholism, delirium, pancreatitis, hypotension, hypertension, pre-existing cardiovascular diseases, head injury (due to the risk of increased intracranial pressure), epileptic disorder or predisposition to convulsions, or patients taking MAO inhibitors.
- Any history of hypersensitivity to Oxycodone / Naloxone or to any of the excipients.
- Active alcohol or drug abuse and/or history of opioid abuse.
- Subjects with evidence of clinically unstable disease, as determined by medical history, clinical laboratory tests, ECG results, and physical examination that, in the Investigator's opinion, preclude entry into the study.
- Subjects who have received an investigational medicinal product within 30 days of study entry (defined as the start of the Screening Period).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01109511
Locations
| Norway | |
| Dept of Anesthesiology, Oslo University Hospital, Ullevaal | Recruiting |
| Oslo, Norway, 0407 | |
| Contact: Johan Raeder +47 92249669 johan.rader@medisin.uio.no | |
| Principal Investigator: Johan Raeder | |
Sponsors and Collaborators
Ullevaal University Hospital
Mundipharma AB
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT01109511 History of Changes |
| Other Study ID Numbers: | targiniqoxycodulleval |
| Study First Received: | April 15, 2010 |
| Last Updated: | July 20, 2011 |
| Health Authority: | Norway:National Committee for Medical and Health Research Ethics |
Additional relevant MeSH terms:
|
Constipation Pain, Postoperative Signs and Symptoms, Digestive Signs and Symptoms Postoperative Complications Pathologic Processes Pain Naloxone Oxycodone Narcotic Antagonists |
Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Narcotics Central Nervous System Depressants Analgesics Analgesics, Opioid |
ClinicalTrials.gov processed this record on June 17, 2013